SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin completes acquisition of brands from Anglo-French Drugs & Industries

07 Apr 2022 Evaluate

Lupin has completed acquisition of a portfolio of brands from Anglo-French Drugs & Industries (AFDIL) and its Associates. The acquisition will strengthen Lupin’s India Formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements and neurological products. The acquisition of the AFDIL brands takes Lupin further in shaping its portfolio to emerge as a leading pharmaceutical company in India.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2379.55 3.55 (0.15%)
04-Aug-2026 09:41 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1950.90
Dr. Reddys Labs. 1156.10
Cipla 1457.65
Lupin 2379.55
Zydus Lifesciences 1120.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: